Pharma BD Deal Intelligence
Vyvanse turned a $2.6B bolt-on into one of the most successful ADHD franchises in pharma history, generating $2B+/year at peak — until a marketing-fraud settlement and 2023 generic cliff closed the chapter.
Full analysis, sources & comparables →Shire agreed to acquire New River for $64/share (~$2.6B all cash) to gain full control of Vyvanse, funded by $2.3B in new debt and $800M of equity.
C&EN noted Vyvanse's prodrug design lowered abuse liability and positioned Shire to defend ADHD share once Adderall XR went generic.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
$64/share, ~$2.6B all-cash. Vyvanse (lisdexamfetamine) ADHD prodrug. Source: SEC, Shire/NRP press release, PharmaTimes.
Vyvanse turned a $2.6B bolt-on into one of the most successful ADHD franchises in pharma history, generating $2B+/year at peak — until a marketing-fraud settlement and 2023 generic cliff closed the chapter.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Shire plc / New River Pharmaceuticals Inc. (this deal) | 2007 | $2.6B | 88 |
| Shire plc / Dyax Corp. | 2016 | $5.9B | 89 |
| Shire plc / Jerini AG | 2008 | $521M | 85 |
| Shire plc / NPS Pharmaceuticals | 2015 | $5.2B | 78 |
| Shire plc / Baxalta Inc. | 2016 | $32.0B | 77 |
| Shire plc / ViroPharma Incorporated | 2013 | $4.2B | 58 |
| Shire plc / Movetis NV | 2010 | $565M | 37 |
← Browse all deals · How we score deals
More: 2007 deals · Shire plc deals